* Castle Biosciences Inc CSTL.OQ reported a quarterly
adjusted
loss of 10 cents per share for the quarter ended in December,
higher than the same quarter last year, when the company
reported EPS of -78 cents. The mean expectation of
nine analysts for the quarter was for a loss of 54 cents per
share. Wall Street expected results to range from -95 cents
to -17 cents per share.
* Revenue rose 72.5% to $66.12 million from a year ago;
analysts
expected $56.28 million.
* Castle Biosciences Inc's reported EPS for the quarter was
a loss
of 10 cents.
* The company reported a quarterly loss of $2.58 million.
* Castle Biosciences Inc shares had risen by 16.3% this
quarter.
FORECAST CHANGES
* The mean earnings estimate of analysts had risen by
about 20.1%
in the last three months.
* In the last 30 days, there have been no negative revisions
of
earnings estimates
RECOMMENDATIONS
* The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 9 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell."
* The average consensus recommendation for the medical
equipment,
supplies & distribution peer group is also "strong buy"
Wall Street's median 12-month price target for Castle
Biosciences Inc is $32.00
This summary was machine generated from LSEG data February 29 at
12:04 a.m. UTC. All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Dec. 31 2023 -0.54 -0.10 Beat
Sep. 30 2023 -0.76 -0.26 Beat
Jun. 30 2023 -0.91 -0.70 Beat
Mar. 31 2023 -0.89 -1.10 Missed